P
Pyramid Biosciences
Dedicated to discovering and developing targeted therapeutics for a wide range of disorders that are regulated by the tropomyosin receptor kinase (TRK) family
About Pyramid Biosciences
Pyramid Biosciences, established in 2015, is a clinical-stage biotechnology firm focused on developing precision medicines for cancer and other molecularly-defined diseases. The company was co-founded by Jordan Leef and Dr. Kollol Pal. Dr. Pal, a serial entrepreneur with extensive experience in the pharmaceutical and biotech industries, has a history of founding and leading successful early-stage companies, including Mnemosyne Pharmaceuticals and Corbus Pharmaceuticals. Mr. Leef brought experience from the financial sector, specifically in private equity and biotechnology equity research, with previous roles at Pharos Capital Group and C.E. Unterberg, Towbin.
The company's business model centers on identifying and advancing therapies that target clinically validated biological mechanisms to address significant unmet medical needs. Pyramid Biosciences generates value through the clinical development and potential commercialization of its therapeutic pipeline, which has been supported by over $60 million in financing from investors such as Adage Capital Management, Oracle Investment Management, and J.W. Childs Associates L.P. This funding has been crucial for accelerating the company's clinical programs.
The core of Pyramid's operations is its pipeline of drug candidates targeting the tropomyosin receptor kinase (TRK) family of receptors. One of its leading programs is PBI-200, an orally-active, central nervous system (CNS) penetrant TRK inhibitor. This drug is engineered to treat a variety of genetically defined cancers, including primary and metastatic brain tumors, and is designed to overcome resistance seen in other TRK inhibitor therapies. Another significant asset is PBI-100, a topical TRK inhibitor being developed for dermatological conditions like psoriasis and atopic dermatitis due to its anti-itch, anti-inflammatory, and antiproliferative properties. In April 2023, the company expanded its oncology portfolio by licensing GQ1010, an antibody-drug conjugate (ADC) targeting TROP2, from GeneQuantum Healthcare for development and commercialization outside of Greater China. The company was acquired by Biohaven in January 2024.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Waltham, United States
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 56.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Pyramid Biosciences is 310 monthly website visits, up 0% over the last three months. Pyramid Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Pyramid Biosciences in the Waltham ecosystem
The Pyramid Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Boston Harbor Angels
Alpine Meridian Ventures
Series A4 investors entered at this stage
Adage Capital
Prospect Hill Growth Partners- OMOracle Investment Management
- AFAverill Master Fund
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Pyramid Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Pyramid Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










